|
Market Closed -
NYSE
23:03:03 01/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 96.69 USD | -2.17% |
|
-4.33% | -22.83% |
| 09-30 | Abbott Launches Simplescreen Crc Blood Test in the U.S | CI |
| 09-30 | Abbott Launches SimpleScreen Blood Test for Colorectal Cancer | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 167,311 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -23.2% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 191,250 | 188,268 | 184,578 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -13.95% | -1.56% | -1.96% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 27.4x | 21.2x | 18.9x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 3.49x | 3.35x | 3.17x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -5.36x | 0.7x | 1.6x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.33x | 3.07x | 2.87x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.81x | 3.45x | 3.17x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 14.7x | 13x | 11.6x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 16.3x | 14.5x | 12.9x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.3x | 21.1x | 19.2x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.95% | 4.74% | 5.2% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.571 | 2.741 | 2.896 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.66% | 2.83% | 2.99% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.53 | 4.553 | 5.106 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 72.8% | 60.2% | 56.7% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,207 | 54,530 | 58,250 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 12,989 | 14,491 | 15,854 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,720 | 13,022 | 14,320 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,303 | 7,978 | 8,906 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,939 | 20,957 | 17,267 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 96.69 | 96.69 | 96.69 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,730,383 | - | - |
| Announcement Date | 1/26/22 A | 1/25/23 A | 1/24/24 A | 1/22/25 A | 1/22/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.39x | 3.81x | 14.72x | 2.66% | 167B | |
| 18.26x | 3.37x | 12.05x | 3.26% | 111B | |
| 21.23x | 4.18x | 14.6x | 1.32% | 105B | |
| 25.57x | 2.51x | 10.15x | 2.82% | 74.82B | |
| 16.96x | 0.2x | 12.44x | 0.77% | 59.11B | |
| 29.74x | 7.35x | 19.01x | 1.35% | 51.8B | |
| 34.32x | 3.34x | 11.44x | 2.2% | 48.5B | |
| 35.06x | 8.71x | 24.52x | -.--% | 40.79B | |
| 34.65x | 6.08x | 19.07x | -.--% | 32.54B | |
| 36.9x | 3.01x | 11.25x | 0.58% | 30.76B | |
| Average | 28.01x | 4.26x | 14.92x | 1.5% | 72.09B | |
| Weighted average by Cap. | 25.85x | 3.93x | 14.32x | 1.93% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- Valuation Abbott Laboratories
Select your edition
All financial news and data tailored to specific country editions
